DailyIQ
|
Sector:HealthcareAll sectors
Last updated 9 minutes ago

ABT·Abbott Laboratories

$.
+. (+.%)
Pre-Market
High
$99.99
Open
$98.30
Market Cap
172.47B
52W High
$137.49
Low
$98.15
P. Close
$98.80
P/E
27.48
52W Low
$81.97
Fwd P/E
16.31
DailyIQ Est.
$120.12
Technical Score (1D)
91
BUY
News Sentiment
86
BULLISH
Abbott’s Q2 earnings beat expectations, driven by stronger‑than‑anticipated sales in Nutrition, Medical Devices and Emerging Markets, which sparked a sharp rally in the stock. The company raised its full‑year 2026 EPS guidance to $5.45–$5.60 and reaffirmed a 6.5%–7.5% comparable sales growth outlook, underscoring confidence in its higher‑margin MedTech and diagnostics mix. Analysts note that the lift follows a strategic pivot away from the lagging Nutrition segment toward devices and diagnostics, a shift that has helped lift margins to around 58%. Wells Fargo upgraded its price target to $112, citing the stronger earnings outlook and Abbott’s pricing actions that have stabilized margins. During the earnings call, management highlighted continued momentum in diagnostics and medical device sales and indicated that regulatory approvals for new devices are on track. Investors should watch the next quarterly earnings release for updates on the product pipeline and any further changes to the 2026 guidance. The shift in product mix also positions Abbott to benefit from rising demand for cancer diagnostics and advanced medical devices, potentially driving additional revenue growth. However, the exact magnitude of the share rally remains uncertain across reports, so traders should focus on the underlying earnings quality rather than price swings.
Earnings Summary
Abbott Laboratories, a global healthcare company founded in 1888, operates across pharmaceuticals, diagnostics, nutritionals, and medical devices, positioning it within the broader medical devices sector. In the most recent two quarters, Q1 2026 and Q2 2026, Abbott posted EPS of $1.15 and $1.31, up from $1.09 and $1.26 in Q1 and Q2 2025, while revenue rose to $11.16 billion and $12.59 billion versus $10.36 billion and $11.14 billion a year earlier, indicating an acceleration in top‑line growth. Over the same period, the company continued its pattern of beating analyst estimates in five of the last seven quarters, with Q1 2025, Q2 2025, Q3 2025, and Q1 2026 all exceeding EPS forecasts, while Q4 2024 and Q4 2025 fell short, and Q2 2026 missed its estimate. Historically, Abbott has maintained steady YoY revenue growth, with each quarter adding roughly $1 billion to the top line, and has delivered positive EPS growth, though occasional misses suggest margin pressure or cost adjustments. Recent news highlights a renewed strategic focus on emerging‑market pharmaceuticals and nutrition, alongside cost‑efficiency initiatives that could lift margins; the company’s acquisition of Exact Sciences and the launch of a colorectal cancer blood test are poised to broaden its diagnostics portfolio, potentially offsetting macro‑economic headwinds and currency volatility. Institutional inflows from Canal Insurance and Diversify Wealth Management signal confidence, while analyst coverage from Baird underscores upside potential tied to new product launches and integration synergies. Investors should watch for guidance revisions in the upcoming Q2 earnings release, particularly regarding diagnostics and devices revenue, the pace of Exact Sciences integration, currency‑hedging disclosures, and any regulatory decisions surrounding the Freenome test, as these factors will shape the next quarter’s earnings trajectory.

EPS

EstBeatMiss
$1.09$1.21$1.33$1.45$1.57Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.42$1.31-7.9%
Q1'26$1.15$1.15+0.3%
Q4'25$1.51$1.50-0.8%
Q3'25$1.30$1.30+0.0%
Q2'25$1.26$1.26+0.3%

Revenue

EstBeatMiss
$10.8B$11.3B$11.8B$12.3B$12.9BQ2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$12.6B$12.6B-0.2%
Q1'26$11.0B$11.2B+1.5%
Q4'25$11.9B$11.5B-3.9%
Q3'25 - $11.4B -
Q2'25 - $11.1B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ABT Stock Snapshot

ABT is currently trading at $99.20, giving Abbott Laboratories a market cap of 172.47B and a P/E ratio of 27.5. Today's range spans $98.15–$99.99, with shares opening at $98.30 and moving up $0.40 (0.4%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 86/100.

Over the past year ABT has traded between $81.97 and $137.49 - the current price is +21.0% off the 52-week low and -27.8% from the high. 37 analysts cover the stock with a Buy consensus and a mean 12-month target of $116.40 (range $92.00–$135.00), implying upside of +17.3%.

ABT is scoring 91/100 technically (BUY) and sits at $99.20 - in the lower half of its 52-week range in its $81.97–$137.49 annual range. Sentiment at 86/100 is bullish. At 172.47B in Healthcare market cap The current P/E ratio stands at 27.5., this is the tier where earnings revision cycles have the most impact on price: upward revisions in a large-cap company with bullish momentum tend to attract analyst upgrades, which in turn attract new institutional mandates.

What makes ABT's BUY setup (91/100) particularly actionable at 172.47B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $99.20 (in the lower half of its 52-week range in $81.97–$137.49), with sentiment running bullish at 86/100, the setup rewards conviction-sized positioning more than it does speculative small bets.